# AEO Retrofit: SGLT2 Inhibitors Article
**Client:** Healthspan
**Target article:** Existing SGLT2 inhibitors article on gethealthspan.com
**Primary AEO target:** "SGLT2 inhibitors for aging how do they work" — AI Overview slot
**Secondary targets:** "are SGLT2 inhibitors longevity drugs", "can non-diabetics take SGLT2 inhibitors"
**Week:** 1 — AEO action (parallel to new content)
**Status:** Ready for publisher implementation
**Date:** 2026-05-07
**Agent:** Content Writer (Tier 3) + SEO Specialist (Tier 3)

---

## What Needs to Be Done

Healthspan already ranks #1 for "SGLT2 inhibitors aging benefits." This retrofit secures the AI Overview slot by adding structured FAQ content and ensuring the article follows AEO formatting conventions. No major rewrite — additive only.

---

## AEO Restructuring Checklist

Apply these changes to the existing article before adding the schema:

- [ ] **Add a direct answer paragraph in the first 100 words** — if the article doesn't immediately answer "how do SGLT2 inhibitors work for aging?", add a 2–3 sentence summary at the top. Example opener: *"SGLT2 inhibitors work for aging by activating AMPK, suppressing mTOR, and inducing mild ketosis — pathways that mimic caloric restriction and reduce systemic inflammation independent of their glucose-lowering effects."*
- [ ] **Check H2 headers mirror search queries** — ensure at least one H2 reads close to: "How Do SGLT2 Inhibitors Work for Longevity?" and another reads "What Is the Evidence for SGLT2 Inhibitors and Aging?"
- [ ] **Add a "Bottom Line" section before the FAQ** — 2–3 sentence paragraph summarizing the key finding. AI engines excerpt this directly.
- [ ] **Add the FAQ section below** — paste verbatim; do not paraphrase
- [ ] **Add the JSON-LD schema to the page `<head>`** — paste verbatim

---

## Bottom Line Paragraph (add before FAQ section)

> SGLT2 inhibitors — originally developed for type 2 diabetes — activate AMPK, suppress mTOR, and promote ketone production through mechanisms independent of blood glucose reduction. These pathways overlap significantly with established longevity biology. Large-scale cardiovascular outcome trials have demonstrated dramatic reductions in mortality and heart failure hospitalization. Preclinical lifespan data and a plausible multi-pathway mechanism support their evaluation as longevity interventions, with human trials in non-diabetic populations now an active area of research.

---

## FAQ Section (add to article body, before citations)

**Frequently Asked Questions**

**How do SGLT2 inhibitors work for aging?**
SGLT2 inhibitors activate AMPK (AMP-activated protein kinase), suppress mTOR, and induce mild ketosis — three mechanisms with direct links to longevity biology. These effects are independent of the drugs' glucose-lowering action and may explain why cardiovascular benefits in trials appeared too quickly to be explained by metabolic improvement alone.

**What are SGLT2 inhibitors?**
SGLT2 inhibitors are a class of drugs that block the SGLT2 protein in the kidneys, preventing glucose reabsorption and causing it to be excreted in urine. Originally developed for type 2 diabetes, they include empagliflozin (Jardiance), dapagliflozin (Farxiga), and canagliflozin (Invokana).

**Can non-diabetics take SGLT2 inhibitors for longevity?**
SGLT2 inhibitors are currently FDA-approved for type 2 diabetes, heart failure, and chronic kidney disease — not for longevity in non-diabetic individuals. Their use in healthy adults for longevity purposes is an off-label application requiring physician evaluation of individual risk-benefit profiles. Healthspan's physicians assess candidacy through a comprehensive biomarker panel before recommending any off-label longevity protocol.

**What is the evidence that SGLT2 inhibitors extend lifespan?**
The strongest human evidence is indirect: the EMPA-REG OUTCOME trial (Zinman et al., NEJM 2015) showed a 38% reduction in cardiovascular mortality with empagliflozin — an effect too rapid for glucose-lowering to explain, suggesting cellular mechanisms. In preclinical research, canagliflozin extended median lifespan in male mice in the NIA Interventions Testing Program (Strong et al., JCI Insight 2022). No large-scale randomized trial has yet tested SGLT2 inhibitors for lifespan extension in non-diabetic humans.

**Are SGLT2 inhibitors the same as metformin?**
No. Metformin and SGLT2 inhibitors are distinct drug classes with different mechanisms, though they share some downstream effects — both activate AMPK and both have longevity interest. Metformin acts primarily on hepatic glucose production and Complex I of the mitochondrial electron transport chain. SGLT2 inhibitors act on renal glucose reabsorption and induce ketosis. They are sometimes combined in longevity protocols.

**What are the main risks of SGLT2 inhibitors?**
The most common adverse effects are genitourinary infections (due to glucosuria) and a small risk of diabetic ketoacidosis in susceptible individuals. Rarer but more serious risks include Fournier's gangrene and, for canagliflozin specifically, lower limb amputation risk in patients with peripheral vascular disease. Risk-benefit evaluation by a physician is essential before use.

**Which SGLT2 inhibitor is most studied for longevity?**
Empagliflozin has the most robust cardiovascular outcome data (EMPA-REG OUTCOME). Canagliflozin has the most direct longevity evidence — it was tested in the NIA ITP and showed lifespan extension in male mice. Dapagliflozin has extensive heart failure and kidney disease outcome data. No head-to-head comparison for longevity-specific endpoints exists.

---

## JSON-LD FAQ Schema (paste into page `<head>`)

```json
{
  "@context": "https://schema.org",
  "@type": "FAQPage",
  "mainEntity": [
    {
      "@type": "Question",
      "name": "How do SGLT2 inhibitors work for aging?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "SGLT2 inhibitors activate AMPK, suppress mTOR, and induce mild ketosis — three mechanisms with direct links to longevity biology. These effects are independent of the drugs' glucose-lowering action and may explain why cardiovascular benefits in trials appeared too quickly to be explained by metabolic improvement alone."
      }
    },
    {
      "@type": "Question",
      "name": "What are SGLT2 inhibitors?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "SGLT2 inhibitors are a class of drugs that block the SGLT2 protein in the kidneys, preventing glucose reabsorption. Originally developed for type 2 diabetes, they include empagliflozin (Jardiance), dapagliflozin (Farxiga), and canagliflozin (Invokana)."
      }
    },
    {
      "@type": "Question",
      "name": "Can non-diabetics take SGLT2 inhibitors for longevity?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "SGLT2 inhibitors are currently FDA-approved for type 2 diabetes, heart failure, and chronic kidney disease. Their use in healthy adults for longevity is off-label and requires physician evaluation of individual risk-benefit profiles."
      }
    },
    {
      "@type": "Question",
      "name": "What is the evidence that SGLT2 inhibitors extend lifespan?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "The EMPA-REG OUTCOME trial showed a 38% reduction in cardiovascular mortality with empagliflozin — an effect too rapid for glucose-lowering alone. Canagliflozin extended median lifespan in male mice in the NIA Interventions Testing Program. No large-scale trial has tested lifespan extension in non-diabetic humans."
      }
    },
    {
      "@type": "Question",
      "name": "Are SGLT2 inhibitors the same as metformin?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "No. Metformin and SGLT2 inhibitors are distinct drug classes with different mechanisms, though both activate AMPK. Metformin acts on hepatic glucose production; SGLT2 inhibitors act on renal glucose reabsorption and induce ketosis. They are sometimes combined in longevity protocols."
      }
    },
    {
      "@type": "Question",
      "name": "What are the main risks of SGLT2 inhibitors?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "The most common adverse effects are genitourinary infections and a small risk of diabetic ketoacidosis. Rarer risks include Fournier's gangrene and, for canagliflozin, lower limb amputation risk in patients with peripheral vascular disease. Physician evaluation is essential."
      }
    },
    {
      "@type": "Question",
      "name": "Which SGLT2 inhibitor is most studied for longevity?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Empagliflozin has the strongest cardiovascular outcome data. Canagliflozin has the most direct longevity evidence from the NIA ITP mouse study. No head-to-head longevity comparison exists between the three main drugs in this class."
      }
    }
  ]
}
```

---

## Publisher Implementation Notes

1. Add Bottom Line paragraph to article body — place it in the final section, before the FAQ
2. Add FAQ section as styled HTML accordion or plain H3/P blocks (both are schema-compatible)
3. Paste JSON-LD into the `<head>` of the article page — not in the body
4. Verify with Google's Rich Results Test after implementation
5. Do not change existing article body content — this is additive only
